drugset / Trial / NCT00759135
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
RandomizedParallel-groupSingle-blindTreatment
Summary
This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-01
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FEXAPOTIDE | Protein / enzyme biologic | 0.125 mg | Other |
| Subject | FEXAPOTIDE | Protein / enzyme biologic | 2.5 mg | Other |
| Comparator | Finasteride | Small molecule | 5 mg | Oral |